NICE has issued new preliminary guidance that does not recommend Pfizer's bosutinib (Bosulif) for patients with previously treated chronic myeloid leukaemia (CML). Bosutinib is licenced for the treatment of patients with CML in those for whom imatinib mesylate (Glivec), nilotinib hydrochloride monohydrate (Tasigna) and dasatinib (Sprycel) are not appropriate. Commenting on the draft guidance, Sir Andrew Dillon, NICE Chief Executive, said: â€œNICE has already recommended two drugs, imatinib mesylate and nilotinib hydrochloride monohydrate for treating different stages of CML, and it is disappointing not to be able to add a third. But NHS resources are limited and NICE has to decide what treatments represent best value to the patient as well as to the NHS. For more details, go to http://www.nice.org.uk/newsroom/pressreleases/NICEConsultsNewTreatmentChronicMyeloidLeukaemia.jsp